Malaria cases, deaths in India decline by 69pc between 2017-2023: WHO

New Delhi, Dec 11 (IANS) India has seen significant progress in reducing malaria incidence and mortality rates, according to the latest World Malaria report, from the World Health Organization (WHO) on Wednesday.

Malaria is a life-threatening disease spread to humans by female Anopheles mosquitoes. It is preventable and curable.

The report showed that the number of estimated malaria cases in India decreased to 2 million cases in 2023 from 6.4 million in 2017 (69 per cent decrease).

Similarly, the estimated malaria deaths decreased to 3,500 from 11,100 (68 per cent decrease) during the same period.

As a result, “India exited the High Burden to High Impact (HBHI) group officially in 2024”, the WHO said.

The HBHI approach is a targeted malaria response that is used in several countries to accelerate the pace of malaria elimination in countries with high malaria burden. India joined the HBHI initiative in July 2019.

The HBHI initiative was launched in four states in India: Chhattisgarh, Jharkhand, Madhya Pradesh, and West Bengal.

Further, the report showed that in 2023, India accounted for half of all estimated malaria cases in the WHO South-East Asia Region, followed by Indonesia, which accounted for just under one-third.

The Region had eight malaria endemic countries in 2023 — accounting for 4 million cases and contributing 1.5 per cent of the burden of malaria cases globally.

Just over 48 per cent of all estimated cases in the region were due to P. vivax.

However, from 2000 to 2023, malaria cases reduced by 82.4 per cent, from 22.8 million in 2000, and incidence reduced by 87.0 per cent, from 17.7 to 2.3 per 1000 population at risk, the report said

“The decrease can mainly be accounted for by a decrease in India of 17.7 million estimated cases and a decrease in incidence by 93 per cent, from 20 to 1.5 per 1000 population at risk,” the WHO reported.

At the same time, India and Indonesia accounted for about 88 per cent of all estimated malaria deaths in this region in 2023.

Notably, Bhutan and Timor-Leste, from the Region, reported zero malaria deaths since 2013 and 2015, respectively, while Sri Lanka was certified malaria-free in 2016.

“The progress follows the highest ever political commitment by Member countries, matched by tangible actions and unstinted efforts over the years down to the sub-national level,” said Saima Wazed, Regional Director WHO South-East Asia.

“However, accelerated efforts against malaria must continue, to eliminate the disease in countries where malaria persists, and to sustain the progress in countries where the disease is on the decline or has been eliminated,” she added.

Globally, the WHO data reveals that an estimated 2.2 billion cases of malaria and 12.7 million deaths have been averted since 2000, but the disease remains a serious global health threat, particularly in the WHO African Region.

In 2023, there were an estimated 263 million cases and 597,000 malaria deaths worldwide — representing about 11 million more cases in 2023 compared to 2022, and nearly the same number of deaths.

“An expanded package of lifesaving tools now offers better protection against the disease, but stepped-up investments and action in high-burden countries are needed to curb the threat,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

–IANS

rvt/

Low-calorie, low-fat snacks see growth as millets surge in India

Mumbai, Dec 11 (IANS) Low-calorie and low-fat snacks are seeing significant growth as millets are being increasingly used in India, according to a report on Wednesday.

The report by NielsenIQ (NIQ), the world’s leading consumer intelligence company, showed that low-calorie, low-fat, and gut-health-focused products dominate, with one in five snacks linked to health.

Millets and mindful snacking are on the rise, alongside health-oriented consumer tech.

It also showed a cultural influence from South Korea. Personal care and food innovations inspired by Korea have gained traction, emphasising unique flavours and textures.

The report noted a growth in demand for sustainably sourced FMCG, and energy-efficient consumer tech tailored to local needs, urbanisation has been fueling the demand for innovative, high-quality products that simplify life.

NIQ Consumer Survey reveals that 34 per cent of urban consumers prioritise new product availability and 40 per cent — especially Gen-Z and women — actively seek innovation claiming to shop for new products before the others did.

“The appetite for novelty is undeniable. For brands, this presents a strategic opportunity to capture consumer interest and drive sustained growth through meaningful and timely innovations,” said Vidya Sen, Executive Director, Customer Success – BASES, NielsenIQ​ said.

NielsenIQ also celebrated the winners of the 2024 Breakthrough Innovation Awards, at a recent event, honouring brands that have disrupted the market and captivated consumers with exceptional new product launches.

These award-winning products launched between 2022 and 2023 and have successfully navigated an ever-evolving consumer landscape.

Since 2012, more than 900 FMCG brands globally have been recognised with this prestigious honour, including about 140 innovations in India across categories like food and beverages (48 per cent) and personal and home care (52 per cent). This year, NIQ also recognised tech and durables brands in India for their groundbreaking achievements in product development and market success.

–IANS

rvt/

Indian scientists develop 1st human gene therapy for Haemophilia A

New Delhi, Dec 11 (IANS) In a significant medical feat, Indian scientists have developed the first-in-human gene therapy using lentiviral vectors for severe haemophilia A

The innovative therapy, developed by the Centre for Stem Cell Research (CSCR) at Christian Medical College (CMC), Vellore — a translational unit of BRIC-inStem, and supported by the Department of Biotechnology, has demonstrated transformational results.

Early this year, scientists at the CMC-Vellore successfully conducted the country’s first human clinical trial of gene therapy for haemophilia A (FVIII deficiency).

The single-centre study, which enrolled five participants aged between 22 and 41 years, showed transformational results.

“The therapy successfully produced zero annualised bleeding rates in all five enrolled participants while enabling prolonged production of Factor VIII, eliminating the need for repeated infusions,” said the scientists, in the paper published in the peer-reviewed New England Journal of Medicine.

This effect was observed “over a cumulative follow-up of 81 months, correlating Factor VIII activity with vector copy numbers in the peripheral blood,” the team said.

Haemophilia A is a severe bleeding disorder caused by the deficiency of clotting Factor VIII. It significantly affects patients’ quality of life, leading to spontaneous bleeding episodes. Although rare, India bears the world’s second-largest burden of haemophilia, with approximately 136,000 cases.

Current treatments require frequent Factor VIII replacement therapy, which faces challenges such as high costs, venous access in children, and low patient acceptance.

The new gene therapy approach involves the use of a lentiviral vector to introduce a normal copy of the Factor VIII gene into autologous haematopoietic stem cells (HSCs).

These modified HSCs generate blood cells capable of producing functional Factor VIII over extended periods.

“Participants were monitored for six months following the gene therapy. Results showed a strong correlation between Factor VIII activity levels and the vector copy number in peripheral blood,” the researchers said.

“This achievement underscores the long-term efficacy and safety of the therapy, offering renewed hope for patients with severe Haemophilia A,” they added.

This pioneering study marks a transformative leap in accessible and effective treatments for resource-limited settings, unlocking new possibilities for managing previously incurable diseases. The therapy is expected to soon undergo a second phase human trial.

–IANS

rvt/

1 person globally acquires new genital herpes infection every second: WHO

New Delhi, Dec 11 (IANS) At least one person each second, or 42 million people annually worldwide is estimated to acquire a new genital herpes infection, according to new estimates by the World Health Organization on Wednesday.

It showed that about 846 million people or more than 1 in 5 people aged between 15 and 49 are living with genital herpes infections.

Herpes simplex virus (HSV), known as herpes, is a common infection that can cause painful blisters or ulcers. It primarily spreads by skin-to-skin contact. It is treatable but not curable.

Usually, these infections cause no or few symptoms, in some cases they lead to painful genital sores and blisters that can recur throughout life, causing significant discomfort and often requiring multiple healthcare visits.

The estimates, published in the journal Sexually Transmitted Infections, showed that over 200 million people suffered at least one such symptomatic episode in 2020.

“While most people with a genital herpes infection experience few symptoms, with so many infections genital herpes still causes pain and distress for millions globally and strains already overburdened health systems,” said Dr Meg Doherty, Director of Global HIV, Hepatitis, and Sexually Transmitted Infections Programmes at WHO.

The alarming figures urge for new treatments and vaccines to reduce the adverse health effects of the herpes virus and control its spread. It will also help “reduce the transmission of HIV,” Doherty said.

HSV are of two types — HSV-1 and HSV-2 — both can lead to genital herpes.

As per estimates, 520 million people in 2020 had genital HSV-2, which is transmitted during sexual activity.

Genital HSV-2 is more serious and it is substantially more likely to cause recurrent outbreaks. It accounts for around 90 per cent of symptomatic episodes and is linked to a three-fold increased risk of getting HIV.

On the other hand, HSV-1 primarily spreads during childhood through saliva or skin-to-skin contact around the mouth to cause oral herpes, with cold sores or mouth ulcers the most common symptoms.

It can also spread via sexual contact. About 376 million people are estimated to have had genital HSV-1 infections in 2020.

Of these, 50 million are estimated also to have HSV-2 as it is possible to have both types at the same time, the WHO said.

The report suggests the correct and consistent use of condoms to reduce the risks of herpes transmission; people with active symptoms should avoid sexual contact.

The WHO also recommends that people with symptoms of genital herpes should be offered HIV testing and if needed, pre-exposure prophylaxis for HIV prevention.

–IANS

rvt/

World Bank to assess MP’s healthcare system for upgradation: Dy CM

Bhopal, Dec 10 (IANS) Madhya Pradesh Deputy Chief Minister Rajendra Shukla on Tuesday said he has urged the World Bank to conduct a thorough assessment of the state’s current healthcare challenges.

He said the World Bank’s study would provide a solid foundation for understanding the existing gaps in the healthcare system and implementing corrective measures.

Shukla, who is also the Health minister of Madhya Pradesh, informed that the delegation has assured to conduct an in-depth study on the state’s healthcare system and will provide its report by March 2025.

Shukla made this statement after chairing a meeting with a delegation of the World Bank representatives here in Bhopal on Tuesday. “World Bank will conduct a comprehensive assessment and propose reforms to empower the state’s healthcare system,” he added.

During the meeting discussion held on various subjects pertaining to the state’s health infrastructure, including the study of health indicators, the rising prevalence of non-communicable diseases (NCDs) and a geographical analysis of disease distribution.

He asserted that addressing the shortage of specialist doctors and other medical manpower in rural areas is a critical challenge that requires both medical and non-medical interventions.

Shukla stressed the importance of optimising the use of healthcare services and resources to ensure that these facilities are accessible to all sections of society.

“The state government is committed to providing timely, accessible, and high-quality healthcare services to every citizen in the state. All possible efforts are being made to strengthen our health infrastructures,” Shukla said.

He informed me that the state government has decided to develop community health centres (CHCs) into first referral units (FRUs) with advanced systems and adequate manpower required for it.

Additionally, medical colleges are being expanded, and large-scale recruitments are being carried out to strengthen the healthcare workforce. He reiterated that these measures aim to improve healthcare delivery and elevate the state’s health indicators.

–IANS

pd/dan

Cambodia bans energy drinks at schools

Phnom Penh, Dec 10 (IANS) Cambodia on Tuesday banned energy drinks at schools as the Southeast Asian country has seen a significant rise in diabetes among young people.

Deputy Prime Minister and Minister of Education, Youth and Sport Hang Chuon Naron said the move was aimed at preventing the risk of non-communicable diseases, especially diabetes, which was caused by the consumption of sugary and energy drinks.

“The consumption, distribution, sale, and advertisement of all kinds of energy drinks in and around schools’ campuses are strictly prohibited,” he said in a directive, Xinhua news agency reported.

He said the prohibition was applied to all public and private educational institutions as well as technical education institutions across the country.

Naron advised all schools to remind students of the effects of having energy drinks when they gathered for the salutation of the national flag.

He also instructed the schools to seize energy drinks from sellers in and around the schools and terminate their stall rental contracts if they defied the ban.

The prohibition came hours after Cambodian Prime Minister Hun Manet said the kingdom has reported an increase in diabetes, advising the Ministry of Education, Youth and Sport to take action to prevent the disease among students.

“Some children consume up to three cans of sugary or energy drinks a day,” he said during a groundbreaking ceremony for the University of Health Sciences Hospital in Phnom Penh.

According to Minister of Health Chheang Ra, diabetes was a major cause of mortality in Cambodia.

He said while infectious diseases were once the primary cause of death in the country, non-communicable diseases currently accounted for more than half of fatalities.

The minister said four main types of non-communicable diseases are heart disease, diabetes, cancer, and chronic respiratory disease.

–IANS

as/

Failure of China’s ‘Zero-Covid’ policy critical lesson for future governance and public health reforms globally (IANS Analysis)

New Delhi, Dec 10 (IANS) The global community experienced extensive lockdowns nearly five years ago to combat the lethal coronavirus SARS-CoV-2, commonly referred to as Covid-19, which was initially identified in Wuhan, China, in late 2019. This pandemic resulted in approximately 6.6 million fatalities worldwide and prompted China to implement a stringent ‘Zero-Covid’ policy aimed at controlling the virus’ spread.

During the first wave, this approach led to over 60,000 deaths within China. Although the policy initially appeared effective, its prolonged enforcement has had detrimental effects on the nation’s socio-economic landscape and public health, consequences that China has yet to fully address.

The execution of this ‘Zero Covid’ strategy by the Chinese Communist Party (CPC) ultimately catalysed the White Paper protests in late 2022, which expressed widespread discontent with the oppressive conditions citizens faced.

Therefore, it is crucial to examine the implications and shortcomings of China’s ‘Zero-Covid’ policy comprehensively.

In August 2020, China implemented its ‘Zero-Covid’ policy to manage local Covid-19 transmissions while aiming to minimise disruptions to the nation’s socio-economic stability. This strategy involved early detection through regular PCR testing and stringent regulations requiring individuals to maintain a ‘normal’ Covid profile, which included presenting negative test results to access public facilities.

Those identified as potential cases were subjected to extended quarantines in government-supervised facilities. Additionally, movement and communication faced rigorous restrictions, with the government monitoring citizens’ mobile phones.

The policy’s aggressive nature was evident in the complete lockdowns of buildings, communities, and even entire cities upon identifying a single potential case.

While many countries began easing lockdown measures, China maintained its strict adherence to the ‘Zero-Covid’ approach. Initially, this swift response garnered praise for safeguarding vulnerable populations and preventing the introduction of new Covid variants from abroad, allowing citizens time to prepare for the pandemic. The ‘Zero-Covid’ policy was largely portrayed as a testament to Xi Jinping’s effective leadership compared to Western responses, fostering public compliance and contributing to its initial success.

However, the subsequent socio-economic crisis revealed that the policy presented more challenges than benefits.

Extended lockdowns and frequent mass testing significantly disrupted daily life and increased the financial burden on the government. Reports of shortages of essential supplies, including food and medical resources, emerged as individuals endured forced quarantines, exemplified by the notorious midnight quarantine in Xi’an.

Furthermore, the overextension of this policy resulted in severe economic repercussions such as sluggish GDP growth, a housing crisis, business closures, and a concerning rise in youth unemployment. The socio-economic distress stemming from movement restrictions and inadequate supplies due to Beijing’s stringent measures also led to significant psychological distress among the population.

Chinese citizens, increasingly disenchanted with the two-year-long ‘Zero-Covid’ policy, have started to publicly voice their dissatisfaction, exemplified by the Sitong Bridge protest in October 2022.

A tragic fire in an apartment building in Urumqi the following month ignited widespread protests against the Chinese government and Xi Jinping’s highly touted ‘Zero-Covid’ strategy. The building that burned had its fire escape doors locked due to over 100 days of government-imposed quarantine, despite the regional capital not experiencing any significant virus outbreaks.

Social media highlighted the government’s inaction during this incident, showcasing fire trucks unable to approach the flames. Consequently, residents of Urumqi took to the streets in protest, which soon evolved into a nationwide movement led by youth known as the White Paper protests.

Demonstrators displayed blank sheets of A4 paper, symbolising government censorship regarding freedom of expression and assembly. Their grievances extended beyond the ‘Zero-Covid’ policy to encompass broader concerns about increasing authoritarianism and surveillance by the government. Slogans were directed against the Communist Party of China (CPC) and Xi Jinping, demanding their resignation.

Thus, the Urumqi fire incident acted as a catalyst for the White Paper protests, reflecting public dissent against the ‘Zero-Covid’ policy and calls for more extensive political reforms in China.

The government’s response to the silent protests involved a heavy-handed police crackdown and widespread detentions. Additionally, the authorities addressed dissent regarding Xi Jinping’s ‘Zero-Covid’ policy through the censorship of protest coverage in state media.

Throughout the duration of the ‘Zero-Covid’ policy, state-controlled media in China has consistently practised censorship.

Notably, Dr Li Wenliang, an ophthalmologist from Wuhan who became known as the ‘whistleblower’ of the virus, faced accusations of “making false comments” when he attempted to alert others about the deadly virus in December 2019.

Following his death, there was a significant public outcry on social media platforms, often referred to as the Wailing Wall, which was routinely censored by the government. Prominent journalists and medical professionals who voiced their opinions against the government’s ‘Zero-Covid’ policy were similarly silenced.

The government further curtailed investigations and halted the publication of data related to Covid outbreaks and fatalities, disseminating inaccurate scholarly findings that were later retracted upon exposure. As global criticism mounted concerning China’s pandemic management, new narratives emerged. Censorship extended beyond data publication to encompass any negative reporting on the ‘Zero-Covid’ policy or expressions of dissent, including those seen during the Wailing Wall, Sitong Bridge protest, and White Paper protests.

The White Paper protests ultimately led to China’s sudden discontinuation of its two-year-long ‘Zero-Covid’ policy in December 2022, leaving citizens to navigate the aftermath on their own, which exacerbated public suffering.

What Xi Jinping had termed a ‘people’s war against Covid’ resulted in a lack of strategic planning, culminating in a significant surge in cases. It is widely believed that the strict and overextended ‘Zero-Covid’ measures, combined with China’s refusal to import effective vaccines and a lackadaisical approach to domestic vaccination efforts, contributed to the low infection rates during lockdowns but also resulted in insufficient natural immunity among the population compared to other countries.

The failure of the ‘Zero-Covid’ policy, along with the ensuing social unrest, serves as a critical lesson for future governance and public health reforms globally, highlighting the necessity to avoid replicating China’s approach.

–IANS

scor/as

123 regular Ayush, 221 e-Ayush visas issued to foreigners in one year: Centre

New Delhi, Dec 10 (IANS) About 123 regular Ayush visas and 221 e-Ayush visas have been issued to foreigners seeking treatment in India, between July 2023 and December 2024, said the Union government on Tuesday.

During the same period, 17 e-Ayush attendant visas have also been issued, said Union Minister of State (Independent Charge) for Ayush Prataprao Jadhav in a written reply in Rajya Sabha.

On July 27, 2023, the Government introduced a separate category of Ayush Visa for foreigners visiting India for availing treatment under the Ayush system of medicine.

Ayush Visa is available under four sub-categories namely: Ayush visa; Ayush attendant visa; e-Ayush visa and e-Ayush attendant visa.

An Ayush Visa is granted to a foreigner whose sole purpose is to seek treatment through Ayush systems.

“A total of 123 regular Ayush Visa, 221 e-Ayush Visa and 17 e-Ayush Attendant Visa have been issued till December 4,” MoS Jadhav said.

The Ministry of Health and Family Welfare also has launched an official portal for Medical Value Travel (MVT), which is the Advantage Healthcare India portal.

The “one-stop” portal aims to facilitate information for those who want to avail medical treatment in India from abroad.

The Government aimed to sensitise the stakeholders like Ayush facility providers and others involved in MVT.

As part of it, the government organised the Ayush Medical Value Travel Summit 2024 in September in Mumbai to boost India’s position in Medical Value Travel (MVT) by integrating traditional Indian systems of medicine with modern healthcare systems.

The theme was ‘Global Synergy in Ayush: Transforming Health and Wellness through Medical Value Travel’.

Meanwhile, MoS Jadhav also informed that the government has adopted a strategy of co-location of Ayush facilities at Primary Health Centres (PHCs), Community Health Centres (CHCs), and District Hospitals (DHs).

It will enable “the choice to the patients for different systems of medicines under a single window”, the MoS said.

–IANS

rvt/svn

Diagnostic platform Redcliffe Labs posts nearly Rs 250 crore loss in FY24

New Delhi, Dec 10 (IANS) Noida-based online diagnostic platform Redcliffe Labs has registered around Rs 250 crore loss in FY24, as its return on capital employed (ROCE) reached -544.68 per cent in the last fiscal year.

The company’s EBITDA margin stood at -57.55 per cent and on a unit basis, Redcliffe Labs spent Rs 1.6 to earn a rupee in FY24, as per its financials.

There was a substantial increase in laboratory test charges and depreciation costs which grew by 62.2 per cent and 3 times, respectively.

As per TheKredible data, Redcliffe Labs has secured $113 million funding to date, including from Leapfrog Investments.

Meanwhile, Redcliffe’s revenue from operations went up 11 per cent to Rs 348.38 crore in FY24 from Rs 313.86 crore in FY23. Its total income stood at Rs 353 crore in the last financial year.

The company’s total expenses stood at Rs 556.16 crore in FY24, from Rs 647.30 crore in FY23.

In September, it secured $42 million in a Series C funding round. IFU, Denmark’s Investment Fund for Developing Countries, led the funding round with $20 million, followed by existing investor LeapFrog Investments with $15 million. The remaining capital was committed by existing shareholders HealthQuad and Spark Growth Ventures.

According to Aditya Kandoi, Founder and CEO, Redcliffe Labs, “our aim is to democratise access to high-quality, affordable, accurate diagnostics for every Indian, with a particular focus on the underserved populations in Tier II and III cities”.

In FY24, Redcliffe clocked cash and bank balances of Rs 15.87 crore and had current assets worth Rs 89.64 crore.

Its services are available in more than 220 cities through its network of over 80 advanced labs powered by 2,000+ collection centres and home collection services, according to the company.

–IANS

na/